Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure

Abstract: Pharmaceutical compositions are disclosed for use in preventing or treating renal failure in mammals which comprise as active ingredient at least one hydantoin derivative of the following formula (I) or a pharmaceutically acceptable salt or complex thereof.

Description: The present invention relates to the use of an hydantoin derivative or a pharmaceutically acceptable salt or complex thereof, for the manufacture of a medicament for inhibiting uremic toxin production in a mammal. Since the number of renal failure patients treated with hemodialysis is increasing, great efforts have been given to the prevention, early detection and treatment of renal failure, and the provision and spread of medical care of dialysis and renal transplantation. Several diseases, for example, various nephropathies such as diabetic nephropathy, nephrosclerosis, collagen disease and obstructive uropathy cause an obstruction of renal functions, and the patients fall into chronic renal failure. In renal failure, quantitative and qualitative homeostasis of body fluid composition cannot be maintained, and it has been suggested that uremic toxins, which are not excreted and are accumulated in the body, cause obstructions and abnormalities of tissues, neuronal and metabolic systems. It is the present situation that there are not any suitable drugs for treating renal failure. Therefore, the developments of good drugs for renal failure are desired, for example, drugs which suppress the production of uremic toxins causing uremic symptoms. It has now been found that certain hydantoin derivatives have a suppressing effect on the production of uremic toxins and an improving effect on renal functions as well as low toxicity and great safety. As disclosed in Japan Kokai Tokkyo Koho JP 1986-122275, 1987-14 and 1987-45525 and EP-A-0 160 618, it was known that the hydantoin derivatives of the present invention had pharmacological effects such as hypoglycemic and hypolipidemic effects. However, a therapeutic effect in connection with renal failure through use of the said compounds has been unknown up till now. An object of the present invention is to provide a pharmaceutical composition for use in preventing or treating renal failure, and especially for reducing abnormally high levels of uremic toxins, in a mammal. The present invention provides the use of a hydantoin derivative of the following formula (I) or a pharmaceutically acceptable salt thereof: wherein each of R 1 and R 2 , which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group, and each of X and Y, which may be the same or different, represents hydrogen, hydroxy, an alkyl group or an alkoxy group, or X and Y together represent an oxo group; and a pharmaceutically acceptable salt or complex thereof, for the manufacture of a pharmaceutical composition for the inhibition of uremic toxin production, or for use in preventing or treating renal failure associated with the production of uremic toxins, in a mammal. In the formula (I), each of R 1 and R 2 , which may be the same or different, represents hydrogen; an alkyl group preferably a straight or branched alkyl group having 1 to 20 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec -butyl, ter t-butyl, pentyl, isopentyl, neopentyl, tert -pentyl, hexyl, dimethylbutyl, heptyl, octyl, nonyl, decyl or stearyl; or a cycloalkyl group, preferably a cycloalkyl group having 3 to 8 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Each of X an Y, which may be the same or different, represents hydrogen; hydroxy; an alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms such as methyl, ethyl, propyl or isopropyl; an alkoxy group, preferably a straight or branched alkoxy group having 1 to 5 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, neopentoxy; or X and Y together represent an oxo group. Preferred compounds of the present invention are indicated as follows: The hydantoin derivatives of the present invention include pharmaceutically acceptable salts of the compounds having formula (I) above, for example, acid addition salts with an acid such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid, perchloric acid, thiocyanic acid, boric acid, formic acid, acetic acid, haloacetic acid, propionic acid, glycolic acid, citric acid, tartaric acid, succinic acid, glyconic acid, lactic acid, malonic acid, fumaric acid, anthranilic acid, benzoic acid, cinnamic acid, p-toluenesulfonic acid, naphthalenesulfonic acid or sulfanilic acid, salts with alkali metals such as sodium or potassium, salts with alkaline-earth metals such as calcium, magnesium or barium, or salts with other metals such as aluminum. The hydantoin derivatives of this invention may also include their metal complexes, for example, complexes with zinc, nickel, cobalt, copper, iron, etc. These salts and metal complexes can be produced from free hydantoin derivatives in the usual way or can be interchanged with each other. When optical isomers exist in the compounds of the invention, the present invention includes any of the d -, l - and dl -isomers. The hydantoin derivatives of the present invention and a process for manufacturing them are disclosed e.g. in Japan Kokai Tokkyo Koho JP 1986-122275, 1987-14 and EP-A-160618. The following is a description of pharmacological studies of the compounds of the present invention. (1) Improving effect on renal function The improving effect on renal function was investigated in rats with chronic renal failure induced by an adenine diet. Adenine-induced chronic renal failure rats were prepared according to the method by Yokozawa et al. [Nephron 51(3), 388-392 (1989)]. Namely, by continuous administration of 0.75% adenine diet for two to five weeks, azotemia, an abnormal urea cycle, an abnormal pattern of free amino acids in the blood and abnormal metabolism of electrolyte were observed together with renal histological changes. These biochemical findings in adenine-fed rats bear close resemblance to metabolic abnormalities in human chronic renal failure. Therefore, the adenine-induced chronic renal failure rats is a suitable experimental model which is useful to study chronic renal failure. The compounds of the present invention were orally administered; this was started at the same time as the beginning of adenine administration. In order to evaluate the efficacy of the test compounds, with renal histological observation, blood urea nitrogen (BUN), phosphate (P) and calcium (Ca) in serum, and uremic toxins such as methylguanidine (MG), creatinine (Cr), guanidinosuccinic acid (GSA) and the like in serum, urine, kidney, liver and muscle were determined by the methods disclosed in the said literature (Yokozawa et al.). Particularly, we focused on methylguanidine, which was regarded as the most important uremic toxin, to study the improving effect on renal function of the compounds of the present invention. Compound 18 was administered for 24 days (250 mg/kg/day), and the results are shown in Tables 1 to 3. Asterisks indicate significant differences (*: p<0.05, **: p<0.01, ***: p<0.001) from the control. [Serum] Control Test compound BUN (mg/dl) 107.4 ± 11.1 71.3 ± 6.7* Cr (mg/dl) 35.5 ± 2.5 24.4 ± 1.5** MG (µg/dl) 7.3 ± 1.3 1.7 ± 0.3*** GSA (µg/dl) 115.4 ± 15.0 22.9 ± 1.1*** P (mg/dl) 14.9 ± 1.2 11.0 ± 0.9* Ca (mg/dl) 7.4 ± 0.5 9.5 ± 0.5* [Urine] Control Test compound Urea (mg/day) 247.3 ± 27.3 353.9 ± 38.3* MG (µg/day) 51.9 ± 4.6 25.7 ± 3.0*** GSA (µg/day) 112.0 ± 13.6 83.8 ± 7.6 [MG (µg/g of tissue)] Control Test compound Liver 0.188 ± 0.030 Not determined Kidney 0.406 ± 0.145 0.239 ± 0.032 Muscle 0.316 ± 0.053 0.143 ± 0.009* In the same manner, the results in the tests using Compound 1 (150 mg/kg/day for 25 days) and Compound 41 (250 mg/kg/day for 14 days) are shown in Table 4. [MG (µg/urine for 6 hrs)] Control Test compound Compound 1 9.8 ± 2.4 6.0 ± 1.9* Compound 41 4.5 ± 0.7 2.3 ± 0.3** According to the pathological observations, histological changes due to kidney morbidity states in the kidneys of rats to which compounds of the present invention were administered, were apparently inhibited as compared with rats subjected to adenine-induced chronic renal failure. As clearly shown by the above-mentioned results, the hydantoin derivatives of the present invention have a normalizing effect on renal functions falling into morbid states. In particular, compounds of this invention significantly lower the high levels of urea nitrogen and phosphate in serum, and also raise the low level of serum calcium and increase the excretion of urea into urine. The results in Tables 1 to 4 show that compounds of the invention have the pharmacological effect of lowering abnormally high levels of uremic toxins such methylguanidine, creatinine, guanidinosuccinic acid in serum, urine and the like down to the normal level permitting increased excretion of urea. A suppressive effect on the production of uremic toxins is one of the mechanisms of the normalizing effect on renal functions produced by compounds of the present invention. The hydantoin derivatives of the present invention significantly suppress the production of uremic toxins which cause uremia symptoms and have an excellent improving effect on renal functions. Therefore, they are useful as preventive medicines or as remedies for chronic renal failure caused by various forms of nephrosclerosis, collagen disease or obstructive uropathy, and it complicated uremic syndrome, such as neuropathy, metabolic and endocrine disorders. Also the compounds of the present invention are useful as drugs improving renal functions which are damaged by the side effects of antineoplastics such as cisplatin, methotrexate and the like. Since the compounds of the invention have low toxicity and great safety, their long-term continuous administration and oral use are possible, so that they can be advantageously used especially in the treatment of such chronic diseases. The compounds of the present invention can be made up into pharmaceutical compositions by combination with appropriate medicinal carriers or diluents, and can be formulated into preparations in solid, semisolid, liquid or gaseous form in usual ways for oral or parenteral administration. In pharmaceutical dosage forms, the compounds of the present invention can be used in the form of their pharmaceutically acceptable salts, and also can be used alone or in appropriate association, as well as in combination with other pharmaceutically active components. In the case of oral preparations, the compounds can be used alone or combined with appropriate additives to make tablets, powders, granules or capsules, e.g. with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatine; with disintegrators such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents. The compounds of the invention can be made into suppositories by admixture with a variety of bases, e.g. fatty and oily base such as cocoa butter, emulsifying bases or water-soluble bases such as macrogol. The compounds of the present invention can be formulated into preparations for injection by dissolving, suspending or emulsifying in aqueous or non-aqueous solvents, such as distilled water for injection, physiologically saline solution, vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acid or propylene glycol. Furthermore, according to the particular disease or patient, the compounds of the invention can be formulated into other preparations suitable for treatment of the disease, such as emulsions, syrups, inhalation products, aerosols, collyrium, ointment and cataplasma. The desirable dose of the compounds of the present invention varies with the subject, the form of the drug, and the method and period of administration. However, in order to obtain desirable effects, generally it is recommended to administer orally 1 to 1,000 mg, preferably 5 to 600 mg daily. Unit preparations are also recommended for administration in one to several units daily. In case of parenteral administrations, e.g. injections, doses of the compounds in the order of one tenth to one third of the above dose are preferable as daily doses. Some prescriptions of the pharmaceutical compositions are shown below as examples which contain the compounds of the present invention as active ingredients. Prescription example 1 (tablet) Component Content in a tablet (mg) compound of this invention 100 lactose 100 crystalline cellulose 40 calcium carboxymethylcellulose 20 magnesium stearate 10 Total 270 mg Prescription example 2 (capsule) Component Content in a capsule (mg) compound of this invention 50 lactose 250 Total 300 mg Prescription example 3 (injection) Component Content in an ampule (mg) compound of this invention 10 sodium chloride proper amount distilled water for injection proper amount Total 1 ml

Claims: Use of a hydantoin derivative of the formula (I): wherein each of R 1 and R 2 , which may be the same or different, represents hydrogen, an alkyl group or cycloalkyl group, and each of X and Y, which may be the same or different, represents hydrogen, an alkyl group or alkoxy group, or X and Y together represent an oxo group; and a pharmaceutically acceptable salt or complex thereof, for the manufacture of a pharmaceutical composition for the inhibition of uremic toxin production in a mammal. Use of a hydantoin derivative of the formula (I): wherein each of R 1 and R 2 , which may be the same or different, represents hydrogen, an alkyl group or cycloalkyl group, and each of X and Y, which may be the same or different, represents hydrogen, an alkyl group or alkoxy group, or X and Y together represent an oxo group; and a pharmaceutically acceptable salt or complex thereof, for the manufacture of a pharmaceutical composition for use in preventing or treating renal failure in a mammal associated with the production of uremic toxins. Use according to claim 1 or claim 2 wherein X and Y are hydrogen. Use according to claim 3 wherein R 2 is hydrogen and R 1 is an alkyl group. Use according to claim 1 or claim 2 wherein X is hydrogen and Y is hydroxy. Use according to claim 5 wherein R 2 is hydrogen and R 1 is an alkyl group. Use according to claim 1 or claim 2 wherein X and Y together represent an oxo group. Use according to claim 7 wherein R 2 is hydrogen and R 1 is an alkyl group. Use according to claim 1 or claim 2 wherein said hydantoin derivative is selected from one or more of 1-methylhydantoin, 5-hydroxy-1-methylhydantoin and 1-methylimidazolidinetrione.

Inventors: IENAGA KAZUHARU, MIKAMI HIROKI, IENAGA, KAZUHARU, MIKAMI, HIROKI, IENAGA, KAZUHARU, C/O INST. OF BIO-ACTIVE SCIENCE, MIKAMI, HIROKI, C/O INST. OF BIO-ACTIVE SCIENCE
Applicants: NIPPON ZOKI PHARMACEUTICAL CO, NIPPON ZOKI PHARMACEUTICAL CO. LTD.
Application year: 1990
Main classification: A61K31
IPC codes: A61P13, C07D233, A61P15, A61K31